8-K: X4 Pharmaceuticals Announces 1-for-30 Reverse Stock Split to Regain Nasdaq Compliance

X4 Pharmaceuticals implements a 1-for-30 reverse stock split, effective April 28, 2025, to increase its stock price and regain compliance with Nasdaq listing requirements.

Summary

• X4 Pharmaceuticals announced a 1-for-30 reverse stock split of its common stock.
• The reverse stock split will be effective at 12:01 a.m. Eastern Time on April 28, 2025.
• Trading on a split-adjusted basis will begin on the Nasdaq Capital Market on April 28, 2025, under the ticker symbol XFOR.
• The reverse stock split will reduce the number of outstanding shares from approximately 173.6 million to approximately 5.8 million.
• Proportional adjustments will be made to equity incentive plans, stock options, and warrants.
• No fractional shares will be issued; stockholders will receive cash in lieu of fractional shares.
• The company received a deficiency letter from Nasdaq on August 13, 2024, due to not maintaining a minimum closing bid price of $1.00 per share.
• Nasdaq granted an additional compliance period until August 11, 2025, contingent on meeting other listing requirements and a plan to cure the deficiency.
• X4 believes the reverse stock split will increase the market price and cure the Nasdaq deficiency.

Sentiment

Score: 5

Explanation: The announcement is neutral. While the reverse stock split is intended to address a negative situation (Nasdaq non-compliance), it's a standard procedure and doesn't necessarily indicate a worsening of the company's prospects. The forward-looking statements are heavily caveated.

Positives

• The reverse stock split aims to increase the stock price and regain compliance with Nasdaq listing requirements.
• The company has a plan to address the Nasdaq deficiency and maintain its listing.
• Existing shareholders will receive cash for fractional shares.

Negatives

• The reverse stock split is a consequence of the company's stock price falling below Nasdaq's minimum bid price requirement.
• The reverse stock split will significantly reduce the number of outstanding shares, which could be perceived negatively by some investors.

Risks

• The reverse stock split may not be sufficient to maintain compliance with Nasdaq listing requirements.
• The company's stock price could continue to decline, leading to further delisting concerns.
• Forward-looking statements are subject to risks and uncertainties, and actual results may differ.

Future Outlook

The company expects the reverse stock split to increase its stock price and cure the deficiency in the Nasdaq Bid Price Rule, but this is subject to risks and uncertainties.

Management Comments

• X4 believes that the reverse stock split will increase the market price for its Common Stock and cure the deficiency in the Bid Price Rule.

Industry Context

Reverse stock splits are often used by companies facing delisting from exchanges due to low stock prices. This action is intended to make the stock more attractive to investors and meet minimum listing requirements.

Comparison to Industry Standards

• Many biotech companies facing similar listing compliance issues have implemented reverse stock splits.
• For example, companies like Bioblast Pharma and Diffusion Pharmaceuticals have used reverse stock splits to maintain their Nasdaq listings.
• The success of a reverse stock split depends on various factors, including the company's underlying financial health and market conditions.

Stakeholder Impact

• Shareholders will have their shares consolidated and may receive cash for fractional shares.
• The reverse stock split aims to maintain the company's listing on Nasdaq, which could benefit shareholders.
• Employees' stock options and equity awards will be adjusted proportionally.

Next Steps

• The reverse stock split will take effect on April 28, 2025.
• The company will monitor its stock price to ensure continued compliance with Nasdaq listing requirements.

Key Dates

Keywords

reverse stock split, Nasdaq, compliance, X4 Pharmaceuticals, XFOR, common stock, listing requirements, stock price, mavorixafor, XOLREMDI